PetVivo Holdings Files 10-K/A Amendment

TL;DR

PetVivo Holdings filed an amendment to its 2024 annual report on 7/9/24. Check for updates.

AI Summary

PetVivo Holdings, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended March 31, 2024. The company, incorporated in Nevada, is involved in the surgical and medical instruments and apparatus industry. This amendment was filed on July 9, 2024, with the SEC.

Why It Matters

This filing provides updated or corrected information for the annual report, which is crucial for investors to have the most accurate financial and operational data for PetVivo Holdings.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, likely for corrections or updates, rather than a new, significant event.

Key Numbers

• 0331 — Fiscal Year End (Indicates the end of the reporting period for the annual report.)
• 001-40715 — SEC File Number (Identifies the company's filing with the SEC.)

Key Players & Entities

• PetVivo Holdings, Inc. (company) — Filer of the 10-K/A amendment
• March 31, 2024 (date) — Fiscal year end for the report
• July 9, 2024 (date) — Date the amendment was filed
• Nevada (jurisdiction) — State of incorporation
• 001-40715 (company_id) — SEC Commission File Number

FAQ

Key Financial Figures

• $9.7 million — received net proceeds of approximately $9.7 million in a registered public offering ("Publi
• $4.50 — ion units at a public offering price of $4.50 per unit. Each unit consisted of one sh
• $5.625 — ur common stock at an exercise price of $5.625 per share. The shares of common stock a
• $11 billion — illion dogs and 1 million horses in the $11 billion companion animal veterinary care and pr
• $600 — le injection of Spryng is approximately $600 to $900 per joint and typically lasts f
• $900 — tion of Spryng is approximately $600 to $900 per joint and typically lasts for at le
• $123.6 billion — tional Pet Owners Survey indicates that $123.6 billion was spent on pets in the U. S. in 2021.
• $34.3 billion — Care and product sales constitute about $34.3 billion of the market. The growth in the U.S. c
• $10,000 — with estimated annual costs as high as $10,000-15,000 per horse to diagnose, treat, an

Filing Documents

• form10-ka.htm (10-K/A) — 411KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• form10-k_001.jpg (GRAPHIC) — 160KB
• 0001493152-24-026619.txt ( ) — 1300KB
• petv-20240331.xsd (EX-101.SCH) — 26KB
• petv-20240331_def.xml (EX-101.DEF) — 28KB
• petv-20240331_lab.xml (EX-101.LAB) — 102KB
• petv-20240331_pre.xml (EX-101.PRE) — 26KB
• form10-ka_htm.xml (XML) — 10KB

Business

Business Description The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals such as cats, dogs and horses. Most of our technology was developed for human biomedical applications, and we intend to leverage the investments already expended in their development to commercialize treatments for horses and companion animals in a capital and time-efficient way. Many of the Company's products are derived from proprietary biomaterials that simulate a body's cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions which incorporate such "tissue building blocks" as collagen, elastin, and proteoglycans such as heparin. Since these are naturally occurring in the body, we believe they have an enhanced biocompatibility with living tissues compared to synthetic biomaterials such as those based upon alpha-hydroxy polymers (e.g PLA, PLGA, and the like), polyacrylamides, and other "natural" biomaterials that may lack the multiple proteins incorporated into our biomaterials. These proprietary protein-based biomaterials that are similar to the body's tissue thus allowing integration and tissue repair in long-term implantation in certain applications. Our initial product, Spryng is a veterinary medical device designed to help reinforce and/or augment articular cartilage tissue for the management of lameness and other joint related afflictions, such as osteoarthritis, in horses and companion animals. Spryng is an intra-articular injectable product of biocompatible and insoluble particles that are slippery, wet-permeable, durable, and resilient to enhance the force cushioning function of the synovial fluid and cartilage. The particles mimic natural cartilage in composition, structure, and hydration. Multiple joints can be treated simultaneously. Our particles are comprised of collagen, elastin, and heparin, similar components found

View Full Filing

View this 10-K/A filing on SEC EDGAR